

# Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation

Kaiwen Chen,<sup>1,2</sup> Matthew P. Cheng,<sup>1,2</sup> Sarah P. Hammond,<sup>1,2</sup> Hermann Einsele,<sup>3</sup> and Francisco M. Marty<sup>1,2</sup>

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, and <sup>2</sup>Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and <sup>3</sup>Department of Internal Medicine II, Universitätsklinikum Würzburg, Würzburg, Germany

Patients treated with allogeneic hematopoietic cell transplantation (HCT) are at risk of cytomegalovirus (CMV) reactivation and disease, which results in increased morbidity and mortality. Although universal antiviral prophylaxis against CMV improves outcomes in solid organ transplant recipients, data have been conflicting regarding such prophylaxis in patients undergoing allogeneic HCT. We conducted a systematic review of randomized trials of prophylactic antivirals against CMV after allogeneic HCT to summarize the evolution of the field over the last 35 years and evaluate the prophylactic potential of antiviral agents against CMV after allogeneic HCT. Electronic databases were queried from database inception through 31 December 2017. For included studies, incidence of CMV infection and all-cause mortality were collected as primary outcomes; CMV disease incidence, use of preemptive therapy, and drug toxicities were collected as secondary outcomes. Nineteen clinical trials conducted between 1981 and 2017 involving a total of 4173 patients were included for review. Prophylactic strategies included use of acyclovir, valacyclovir, ganciclovir, maribavir, brincidofovir, and letermovir compared with placebo or a comparator antiviral. Fourteen trials that compared antiviral prophylaxis with placebo demonstrated overall effectiveness in reducing incidence of CMV infection (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.42-0.58), CMV disease (OR, 0.56; 95% CI, 0.40-0.80), and use of preemptive therapy (OR, 0.51; 95% CI, 0.42-0.62; 6 trials); however, none demonstrated reduction in all-cause mortality (OR, 0.96; 95% CI, 0.78-1.18) except the phase 3 trial of letermovir (week-24 OR, 0.59; 95% CI, 0.38-0.98). Additional research is warranted to determine patient groups most likely to benefit from antiviral prophylaxis and its optimal deployment after allogeneic HCT.

## Introduction

Human cytomegalovirus (CMV) is an enveloped double-stranded DNA virus that belongs to the herpesviridae family. Infection with CMV is common, with seroprevalences ranging from 50% to over 90% depending on age, geographical location, and socioeconomic factors.<sup>1</sup> CMV establishes latency in human epithelial tissue, polymorphonuclear cells, myeloid progenitors, and T lymphocytes and is normally controlled by the host's immune system.<sup>2,3</sup> Immunosuppression after allogeneic hematopoietic cell transplantation (HCT) frequently leads to CMV reactivation, which is associated with increased morbidity and mortality in this patient population.<sup>4-6</sup> Primary CMV infection and reactivation increase the risk of CMV disease after allogeneic HCT, which can manifest clinically in diverse ways, including colitis, pneumonitis, retinitis, and hepatitis.<sup>7,8</sup> Recent studies have also shown that despite use of preemptive

therapy, CMV reactivation may be associated with an increased risk of invasive fungal disease<sup>8</sup> and is also an independent risk factor for nonrelapse mortality.<sup>9</sup>

The evolution of effective antiviral agents against CMV has resulted in the emergence of 2 distinctive strategies to prevent CMV-related outcomes among patients undergoing HCT: universal prophylaxis and preemptive therapy. The latter is defined as antiviral treatment triggered by early detection of active CMV infection, before clinical disease occurs. Specifically, patients undergo blood CMV surveillance with viral DNA or antigen detection, and antiviral therapy is initiated above a certain detection threshold.<sup>10,11</sup> However, any level of CMV viremia has been associated with increased nonrelapse mortality after allogeneic HCT, despite use of highly sensitive diagnostic assays to detect low-level CMV viremia.<sup>12</sup> This disadvantage highlights the need for safe and effective antiviral agents to be used in prophylactic strategies.

The quest for successful prophylactic strategies against CMV for allogeneic HCT patients started in the 1980s. Although universal prophylaxis was effective in preventing CMV primary infection and reactivation after transplantation in some trials, the overall benefit of prophylactic agents has been difficult to assess. Universal prophylaxis has been associated with toxicities particularly detrimental after HCT, including clinically significant myelosuppression associated with ganciclovir and valganciclovir use, which may increase nonrelapse mortality.<sup>13</sup>

We conducted a systematic review of all antivirals that have been studied for universal prophylaxis to reduce risk of CMV infection among patients undergoing allogeneic HCT. This review assesses the overall efficacy of antiviral prophylaxis in view of novel antiviral therapies and increasingly sensitive diagnostic tests and puts these into perspective with letermovir, which was recently approved for CMV prophylaxis in this patient population.

## Methods

### Data sources and searches

This manuscript was prepared and reported using PRISMA guidelines and registered in PROSPERO in 2016 as #CRD42016052180.<sup>14</sup> PubMed electronic databases were queried from database inception to 31 December 2017. Search terms combined MeSH terms, text words, and exploding terms, including cytomegalovirus, CMV, allogeneic, stem-cell transplant, hematopoietic cell transplant, bone marrow transplant, and prophylaxis. The complete strategy and search terms are listed in supplemental Table 1 of the supplemental Material. The search was limited to articles published in English. Additional studies were identified from references from relevant articles.

### Study selection and quality assessment

We included randomized clinical trials involving IV or oral antiviral prophylaxis where CMV infection or CMV disease was a measured outcome. Nonrandomized trials, nonprophylactic trials involving preemptive therapy, and nonantiviral therapies were excluded. Studies of patients who had undergone allogeneic HCT irrespective of age, CMV serostatus, transplantation conditioning regimen, or HLA matching were included. Any intervention that compared an antiviral agent with either placebo or a different antiviral early after HCT (before day +100) with the intent of preventing initial episodes of CMV infection or disease posttransplantation was considered. Authors of selected papers were contacted for additional data if key

outcomes were not reported. Study quality was assessed using a standardized tool in Review Manager 5.3 (Cochrane Collaboration, Copenhagen, Denmark) based on the Cochrane handbook, where selection, performance, detection, attrition, and reporting biases were assessed.<sup>15</sup>

### Outcome measures

To evaluate the efficacy of CMV prophylaxis, 2 primary outcomes were assessed. The first was to determine the effect of antiviral prophylaxis on incident CMV primary infection or reactivation. The second was to determine all-cause mortality through follow-up. Secondary end points included rate of preemptive therapy for CMV reactivation while receiving prophylaxis, incidence of CMV disease, and antiviral drug-related toxicity. The primary and secondary outcomes were obtained by referring to end points prespecified in the individual studies, but outcomes up to a year were captured if data were available.

### Data extraction and collection

Two independent reviewers (K.C. and M.P.C.) first assessed the titles and abstracts of the search results for eligibility. The full text of the eligible studies was then reviewed for inclusion. The reviewers then designed a data collection form to document authors, year of publication, definition of CMV infection, CMV infection rate, all-cause mortality rate, preemptive therapy rate, antiviral drug used, dosing information and timeline, days of treatment, days of follow-up, type and frequency of CMV measurement, and predefined end points for each study. A formal metaanalysis was not performed because of the heterogeneity in study design and diagnostic methods over time.

### Data synthesis and analysis

Data summary and figures were generated in Review Manager 5.3 (Cochrane Collaboration).<sup>15</sup> Dichotomous data were analyzed and presented using forest plots, which summarized treatment effect on all-cause mortality, CMV disease, CMV incidence (as defined by study parameters), and preemptive therapy rate if available. Secondary outcomes, such as drug toxicity and study characteristics, were summarized in tables for qualitative analysis.


## Results

### Included studies

The electronic searches retrieved 225 unique results. After reading the titles and abstracts, 11 trials were selected for full review. Of these, 1 was not a prophylaxis trial, and 1 was not randomized. Ten additional studies were selected through identification of relevant references. A trial of late CMV prophylaxis comparing valganciclovir with placebo beginning after day +100 that included patients with prior episodes of CMV infection was not considered further.<sup>16</sup> Nineteen trials were included in this review (Figure 1). Fourteen studies compared an antiviral prophylaxis with placebo, whereas 5 studies compared one antiviral with another.

A total of 4173 patients were randomly assigned in prospective trials and analyzed for the primary outcomes analyses. Of these patients, 58% were male, with an estimated median age of 41 years (range, 1-78 years). The most common underlying malignancy was acute leukemia (46%), followed by myelodysplastic syndrome

**Figure 1. Systematic review flow diagram.**




(12%), lymphoma (12%), and chronic myeloid leukemia (11%). Description of key study characteristics, trial intervention, and standard-of-care CMV management of each study can be found in Table 1. Antiviral drugs used included acyclovir, valacyclovir, ganciclovir, maribavir, brincidofovir, and letermovir. Follow-up times after antiviral prophylaxis ranged from 0 to 265 days, with 14 of 19 studies having at least 28 days of follow-up. Study design outlines,

including length of prophylactic treatment and follow-up period, are shown in Figure 2.

### Risk of bias in included studies

Four studies<sup>17-20</sup> were judged to be at high risk of reporting bias because of incomplete reporting of outcome measures. The full summary and graphs for risk of bias can be found in supplemental



**Figure 2. Timelines of trials reviewed.**

Figures 1 and 2. The overall quality of the studies was good. Allocation bias was the most common risk identified, because most studies did not report their allocation or randomization methods.<sup>20-30</sup> Four studies randomly assigned patients using a form of interactive voice or Web response system.<sup>31-35</sup> One study randomly assigned patients using a computer-generated table of random numbers.<sup>19</sup> Fourteen of 19 studies were double blinded,<sup>18-20,22,23,25,26,29-35</sup> whereas 5 studies did not mention blinding and were assumed to be open label.<sup>17,21,24,27,28</sup> Because adverse event reporting can be biased in open-label studies, these studies should be judged carefully in their reporting of drug-related toxicity. A minority of studies had incomplete outcome data.<sup>17,18,27</sup> One study did not have results on CMV infection rate.<sup>22</sup> Three studies lacked results on CMV disease in treatment or control arm as well as adverse event or toxicity data<sup>17,18,20</sup> (Tables 1 and 2).

## Effects of interventions

Because of changing CMV detection standards, the approach to CMV management has evolved over time. Before 2002, a majority of CMV primary infection, reactivation, and disease diagnoses were based on CMV culture. Around 2004, trial diagnostic methods shifted toward culture-independent techniques, including antigenemia and polymerase chain reaction (supplemental Table 3). Supplemental Table 2 summarizes each CMV detection technique used by each study. For phase 2 dose-ranging studies, each dose level is presented separately. Forest plots summarizing all-cause mortality, CMV disease, CMV infection, and preemptive therapy incidences to the predefined end point periods of the individual trials that compared antivirals with placebo are presented in Figure 3. Overall, the 14 trials that compared antiviral prophylaxis with placebo demonstrated effectiveness in reducing incident CMV infection (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.42-0.58), CMV disease (OR, 0.56; 95% CI, 0.40-0.80), and use of preemptive therapy (OR, 0.51; 95% CI, 0.42-0.62; 6 trials) but not all-cause mortality (OR, 0.96; 95% CI, 0.78-1.18). The most relevant toxicity and adverse event data are shown in Table 2.

## Acyclovir

The first antiviral studied for universal prophylaxis against CMV was acyclovir, with a total of 8 studies published from 1981 to 2006; some studies did not report enrollment periods.<sup>17-24</sup> Five studies were placebo controlled, and 1 study each compared acyclovir with IV ganciclovir, IV acyclovir, and oral valganciclovir. These studies had a total of 1347 participants and initiated prophylaxis between days -8 to -3 before transplantation. Treatment continued for a median time of 102 days (range, 18-216 days), and follow-up continued for a median time of 69 days (range, 0-335 days). The overall results were mixed (Figure 3) and suggested that acyclovir was associated with low toxicity after allogeneic HCT (Table 2). However, although a delay in the onset of CMV reactivation was demonstrated, acyclovir showed nonsignificant efficacy in preventing CMV disease (Figure 3; supplemental Figure 3).

## Ganciclovir

The next antiviral agent studied was ganciclovir, with 5 reported studies spanning from 1990 to 1998.<sup>25-28,30</sup> Three studies compared IV ganciclovir against placebo, 1 compared IV ganciclovir against valganciclovir, and 1 compared oral ganciclovir against IV ganciclovir (supplemental Figure 4). A total of 647 participants were included in these studies. Median treatment time was 101 days

(range, 84-128 days), and median follow-up time was 80 days after treatment (range, 0-265 days). These studies suggested that ganciclovir was effective in reducing incidence of CMV infection and CMV disease after allogeneic HCT but was not associated with a reduction in all-cause mortality, likely secondary to drug discontinuation related to clinically significant myelosuppression (Figure 3; supplemental Figure 4; Table 2).

## Maribavir

In the last 10 years, 3 novel antivirals have emerged as potential CMV prophylactic candidates and have been studied in an era of highly sensitive molecular testing. Two studies involved maribavir, which is a UL97 viral protein kinase inhibitor that prevents nuclear egress of CMV virions.<sup>36,37</sup> The studies included 792 HCT participants recruited from 2004 to 2008.<sup>29,34</sup> Median treatment time was 84 days (range, 1-92 days), and median follow-up time after treatment was 147 days (range, 56-238 days). Although a dose-escalation phase 2 trial had demonstrated antiviral activity at doses ranging from 100 to 400 mg twice daily,<sup>29</sup> the results of the phase 3 trial demonstrated that maribavir at 100 mg twice daily started after engraftment had no significant effect on incidence of CMV disease, CMV reactivation, or preemptive therapy for CMV after allogeneic HCT compared with placebo by HCT week 24 and had no statistically significant effect on mortality (Figure 3).<sup>34,38</sup> Maribavir was largely well tolerated; the proportion of patients with adverse events leading to study drug discontinuation and serious adverse events was largely the same between maribavir and placebo arms. However, patients receiving 400 mg of maribavir twice daily in the phase 2 trial experienced increased rates of nausea and taste disturbance (Table 2).<sup>29</sup>

## Brincidofovir

Brincidofovir (CMX001) is an oral lipid conjugate formulation of cidofovir and was recently evaluated in 2 randomized placebo-controlled studies for prevention of CMV infection in HCT recipients from 2009 to 2015.<sup>32,33</sup> In total, 682 participants were treated for a median duration of 66.5 days (range, 1-99 days) and followed for a median time of 71 days (range, 70-72 days) after treatment. Although a phase 2 dose-ranging trial demonstrated significantly lower CMV events with brincidofovir at a dose of 100 mg twice weekly and a treatment completion rate of 60% when started after engraftment through week 13 post-HCT,<sup>33</sup> brincidofovir did not improve CMV-related outcomes in the phase 3 trial that evaluated treatment at 100 mg twice weekly against placebo beginning a median of 15 days post-HCT (Figure 3), with a low completion rate (38%).<sup>32</sup> Furthermore, brincidofovir was associated with increased rates of diarrhea, acute GVHD with gastrointestinal involvement, other gastrointestinal adverse events, and a nonsignificant increased risk of death when compared with placebo (Table 2).<sup>32,33</sup>

## Letermovir

Letermovir is an antiviral agent with a novel mechanism of action involving inhibition of the human CMV terminase complex.<sup>39-43</sup> It was studied in 2 randomized placebo-controlled studies for CMV prophylaxis from 2010 to 2016 with a total of 686 HCT participants.<sup>31,35</sup> In these studies, median treatment time was 77.5 days (range, 1-113 days), and median follow-up time was 122.5 days (range, 7-238 days). Among patients undergoing allogeneic HCT, letermovir at a dose of 480 mg per day (or 240 mg per day when administered concomitantly with cyclosporine) was

**Table 1. Randomized trials of CMV prophylaxis in allogeneic HCT patients analyzed**

Study	Year	Methods	Participant characteristics	Study intervention	SOC CMV management	Outcomes measured
19	1981	Randomized, double blind, placebo controlled, parallel groups	Transplantation type: allogeneic (16), autologous (3), syngeneic (1) Age range: 6-51 y Inclusion: HSV antibody titers $\geq 1:8$	Patients randomized 1:1 to IV acyclovir 250 mg/m <sup>2</sup> every 8 h or placebo from d -3 for total of 18 d	No additional management specified	HSV Infection, CMV infection
17	1983	Randomized, double blind, placebo controlled, parallel groups	Transplantation type: matched RD or syngeneic	Patients randomized 1:1 to oral acyclovir 200 mg every 6 h or placebo from d -8 to d +35	No additional management specified	HSV infection, CMV infection, effect of acyclovir on GVHD and survival
18	1983	Randomized, double blind, placebo controlled, parallel groups	Transplantation type: allogeneic matched or mismatched RD Serostatus: HSV R+	Patients randomized 1:1 to IV acyclovir 5 mg/kg every 12 h or placebo during neutropenia ( $ANC < 1 \times 10^9/L$ )	No additional management specified	Incidence of HSV, incidence of CMV infection or disease, days of neutropenia
20	1986	Randomized, double blind, placebo controlled, parallel groups, stratified by HSV serostatus	Transplantation type: allogeneic marrow transplantation Age: $\geq 2$ y	Patients randomized 1:1 to IV acyclovir 250 mg/m <sup>2</sup> twice a day from d -5 to d +35, transitioned to oral acyclovir 400 mg every 8 h until d +180	No additional management specified	Incidence of HSV infection, VZV infection, CMV infection
25	1993	Randomized, double blind, placebo controlled, parallel groups	Transplantation type: allogeneic marrow transplantation using total-body irradiation or busulfan-cyclophosphamide Age: $\geq 2$ y Serostatus: CMV R+	Patients randomized 1:1 to IV ganciclovir 5 mg/kg twice daily or placebo beginning at engraftment for 5 d, then 5 mg/kg per day to d +100	Upon positive viral cultures, patients removed from blinded study drug and treated with IV ganciclovir	Incidence of CMV infection, CMV disease, neutropenia
26	1993	Randomized, double blind, parallel groups, placebo controlled	Transplantation type: allogeneic Age: $\geq 12$ y Serostatus: CMV R+	Patients randomized 1:1 to IV ganciclovir 2.5 mg/kg every 8 h from d -7 to d -1, then from engraftment ( $ANC \geq 1 \times 10^9/L$ ) to d +120 6 mg/kg per day Mondays through Fridays, or placebo Drug held for $ANC < 1 \times 10^9/L$ , resumed at 6 mg/kg per d 3 times per wk	Upon diagnosis of clinical CMV disease, patients removed from blinded study and treated with IV ganciclovir	CMV infection, CMV disease, study drug toxicity
21	1994	Randomized, double blind, double dummy, 3 parallel groups	Transplantation type: HLA matched related or unrelated allogeneic Age: $\geq 2$ y Serostatus: CMV R+ or D+	Patients randomized 1:1:1 to 1 of 3 arms Arm A: IV acyclovir 500 mg/m <sup>2</sup> every 8 h from d -5 to d +30, followed by oral acyclovir 800 mg every 6 h until 6 mo posttransplantation, adjusted to renal function Arm B: IV acyclovir like arm A, placebo until 6 mo posttransplantation Arm C: 400 mg oral acyclovir every 6 h from d -5 to d +30, then placebo	CMV disease or CMV infection treated at discretion of site investigator	Time to CMV infection, survival, time to CMV viremia
30	1996	Randomized, double blind, parallel groups	Transplantation type: all allogeneic Age: all ages Serostatus: CMV R+	Patients randomized 1:1 to IV ganciclovir 5 mg/kg twice daily or placebo beginning at engraftment for 5 d, then 5 mg/kg per day 6 d per wk to d +100 Patients underwent CMV antigenemia testing and treated with IV ganciclovir with antigenemia of $\geq 3$ cells per 2 slides	If antigenemia or CMV viremia detected, study drug stopped, and IV ganciclovir administered	CMV disease, neutropenia
23	2002	Randomized, double blind, parallel groups	Transplantation type: allogeneic matched or mismatched, related or unrelated Age: $\geq 13$ y Serostatus: CMV R+ or D+	All patients treated with IV acyclovir 500 mg/m <sup>2</sup> every 8 h from d -5 to d +28, then randomized 1:1 into 2 arms Arm A: oral valacyclovir 2 g every 6 h until end of wk 22 posttransplantation Arm B: oral acyclovir 800 mg every 6 h until end of wk 22 posttransplantation All doses adjusted to creatinine clearance	Preemptive therapy with IV ganciclovir or foscarnet based on laboratory evidence of infection, according to study site usual practice	Time to detection of CMV, time to death, time to CMV viremia, time to onset of CMV disease, time to other antiviral use, time to onset of CMV infection

ANC, absolute neutrophil count; D, donor; GVHD, graft-versus-host disease; HSV, herpes simplex virus; PCR, polymerase chain reaction; R, recipient; RD, related donor; SOC, standard of care; VZV, varicella zoster virus.



Table 1. (continued)

Study	Year	Methods	Participant characteristics	Study intervention	SOC CMV management	Outcomes measured
24	2002	Randomized trial, parallel groups	Transplantation type: allogeneic related or unrelated Age range: 1-55 y Serostatus: CMV R+	All patients received IV ganciclovir 5 mg/kg twice daily from d -7 to -2, followed by IV acyclovir 10 mg/kg every 8 h from d -1 to engraftment; patients then randomized 1:1 into 2 arms  Arm A: oral acyclovir 800 mg in adults, 18 mg/kg children, 5 times per day Arm B: IV ganciclovir 5 mg/kg every weekday until d +100  All patients received IV immunoglobulin 500 mg/kg on days -6, 0, 7, 21, 35, 55, 76, 98	Upon detection of antigenemia, prophylaxis discontinued, and patients treated preemptively with administration of IV ganciclovir or foscarnet	Incidences of CMV antigenemia and CMV disease, adverse events
28	2003	Randomized trial, parallel groups	Transplantation type: allogeneic related or unrelated Age: $\geq 13$ y Serostatus: CMV R+	All patients received IV acyclovir 500 mg/m <sup>2</sup> every 8 h from d 0 to engraftment (ANC $\geq 750$ cells/ $\mu$ L for 2 d); patients then randomized 1:1 into 2 arms  Arm A: oral valacyclovir 2 g every 6 h from engraftment to d +100 Arm B: IV ganciclovir 5 mg/kg twice daily for 1 wk, then 6 mg/kg once daily 5 d per week  Doses reduced for patients with renal dysfunction	Treatment of CMV infection or disease at discretion of site investigators	Incidences of CMV infection and CMV disease, incidence of neutropenia, survival
27	2004	Randomized trial, parallel groups	Transplantation type: allogeneic Serostatus: CMV R+ or D+	IV ganciclovir 5 mg/kg twice daily from d -8 to d -1 for CMV R+  Acyclovir 400 mg orally or 250 mg IV every 8 h for HSV R+  Randomized at engraftment 1:1 (ANC 500/ $\mu$ L and unsupported platelet recovery $>20 \times 10^9$ /L)  Arm A: IV ganciclovir 5 mg/kg 3 times weekly to d +84 Arm B: oral ganciclovir 1 g every 8 h to d +84	No additional management specified; patients who stopped oral ganciclovir early treated with IV ganciclovir	Incidences of CMV infection, CMV disease
22	2006	Randomized, double blind, placebo controlled, stratified by presence of GVHD	Transplantation type: allogeneic Age: $\geq 10$ y Inclusion: history of chicken pox	All patients seropositive to HSV given prophylactic acyclovir 250 mg/m <sup>2</sup> every 12 h from d -7 to d +30  Patients randomized 1:1 oral acyclovir 800 mg twice daily and started study drug between d 30 and d 100 and continued until 1 y after transplantation	CMV-specific management not mentioned	VZV disease at 1 y after transplantation, VZV infection after 1 y, HSV infection, CMV disease, toxicity, survival, VZV- and HSV-specific immune reconstitutions
29	2008	Randomized, double blind, placebo controlled, stratified by transplantation type, sequential dose-escalation groups	Transplantation type: allogeneic Age: $\geq 18$ y Serostatus: CMV R+	Randomized 3:1 to maribavir or placebo, dosing began at engraftment, d 14-30 after transplantation  Arm A: maribavir 100 mg twice daily Arm B: maribavir 400 mg daily Arm C: maribavir 400 mg twice daily Arm D: matching placebo twice daily, pooled from each dose level	Upon detection of CMV infection or diagnosis of CMV disease, study drug discontinued, and patients treated with anti-CMV antiviral at discretion of site investigators	Incidence and time of onset of CMV infection or CMV disease, incidence of CMV disease alone, use of preemptive antiviral therapy

ANC, absolute neutrophil count; D, donor; GVHD, graft-versus-host disease; HSV, herpes simplex virus; PCR, polymerase chain reaction; R, recipient; RD, related donor; SOC, standard of care; VZV, varicella zoster virus.



**blood advances**

ANC, absolute neutrophil count; D, donor; GVHD, graft-versus-host disease; HSV, herpes simplex virus; PCR, polymerase chain reaction; R, recipient; RD, related donor; SOC, standard of care; VZV, varicella zoster virus.

**Table 2. Summary of adverse events**

Study	Study characteristics		Serious adverse event incidence		Most common drug-related adverse events	
	Experimental intervention	Control intervention	Experimental arm	Control arm	Experimental arm	Control arm
19	IV acyclovir	Placebo	Not provided	Not provided	Serum AST > twice normal (60%)	Serum AST > twice normal (50%)
17	Oral acyclovir	Placebo	Not provided	Not provided	Not provided	Not provided
18	IV acyclovir	Placebo	Not provided	Not provided	Nausea and vomiting (50%)	Nausea and vomiting (80%)
20	IV acyclovir	Placebo	Not provided	Not provided	Not provided	Not provided
25	IV ganciclovir	Placebo	Not provided	Not provided	Neutropenia (30%)	Neutropenia (0%)
26	IV ganciclovir	Placebo	Not provided	Not provided	Neutropenia requiring treatment interruption (58%)	Neutropenia requiring treatment interruption (28%)
21	IV acyclovir extended IV acyclovir short course	Oral acyclovir	Not provided	Not provided	Nausea (4%-8%)* Vomiting (3%) Renal failure (7%-13%)*	Nausea (4%) Vomiting (3%) Renal failure (9%)
30	IV ganciclovir	Placebo	Not provided	Not provided	Neutropenia (25%) Any bacterial infection (45%) Invasive fungal disease (16%)	Neutropenia (32%) Any bacterial infection (40%) Invasive fungal disease (6%)
23	Valacyclovir	Oral acyclovir	Not provided	Not provided	Nausea (24%) Vomiting (22%) Abdominal pain (19%) Diarrhea (19%)	Nausea (21%) Vomiting (22%) Abdominal pain (16%) Diarrhea (21%)
24	IV ganciclovir	Oral acyclovir	Not provided	Not provided	Secondary neutropenia (62%) Renal insufficiency (38%)	Secondary neutropenia (39%) Renal insufficiency (33%)
28	Valacyclovir	IV ganciclovir	Not provided	Not provided	Neutropenia (32%) Renal insufficiency (6%) Nausea, vomiting (5%)	Neutropenia (13%) Renal insufficiency (10%) Nausea, vomiting (8%)
27	IV ganciclovir	Oral ganciclovir	Not provided	Not provided	Not provided	Not provided
22	Oral acyclovir	Placebo	Not provided	Not provided	Gastrointestinal effects (8%) Pancytopenia (3%) Increased liver function tests (3%)	Neutropenia (3%)
29	Maribavir 100 mg twice daily Maribavir 400 mg daily Maribavir 400 mg twice daily	Placebo Placebo Placebo	Not provided Not provided Not provided	Not provided Not provided Not provided	Taste disturbance (18%-31%)* Nausea (7%-15%)* Vomiting (4%-11%)*	Taste disturbance (0%) Nausea (0%) Vomiting (4%)
34	Maribavir 100 mg twice daily	Placebo	197/451 (44%)	98/223 (44%)	Acute GVHD (36%) Diarrhea (21%) Fatigue (16%)	Acute GVHD (33%) Diarrhea (19%) Fatigue (10%)
33	Brincidofovir 40 mg weekly Brincidofovir 100 mg weekly Brincidofovir 200 mg weekly Brincidofovir 200 mg biweekly Brincidofovir 100 mg biweekly	Placebo Placebo Placebo Placebo Placebo	12/25 (48%) 10/27 (37%) 19/39 (49%) 21/30 (70%) 30/50 (60%)	27/59 (46%)	Diarrhea (12%-70%)* Vomiting (8%-44%)* Acute GVHD (32%-80%)*	Diarrhea (27%) Abdominal pain (7%) Acute GVHD (29%)

AST, aspartate aminotransferase.

\*Range provided for different treatment arms and dose levels.



Table 2. (continued)

Study	Study characteristics		Serious adverse event incidence		Most common drug-related adverse events	
	Experimental intervention	Control intervention	Experimental arm	Control arm	Experimental arm	Control arm
35	Letermovir 60 mg daily Letermovir 120 mg daily Letermovir 240 mg daily	Placebo Placebo Placebo	9/33 (27%) 12/31 (39%) 9/34 (26%)	12/33 (36%)	Gastrointestinal disorders (52%-76%)* Infections (52%-59%)* Skin and cutaneous tissue disorders (39%-55%)*	Gastrointestinal disorders (61%) Infections (76%) Skin and cutaneous tissue disorders (33%)
32	Brincidofovir 100 mg biweekly	Placebo	173/303 (57%)	56/149 (38%)	Diarrhea (61%) Acute GVHD (57%) Abdominal pain (34%)	Diarrhea (36%) Acute GVHD (32%) Abdominal pain (17%)
31	Letermovir 480 mg daily	Placebo	193/373 (52%)	109/192 (57%)	GVHD (39%) Diarrhea (26%) Nausea (27%)	GVHD (39%) Diarrhea (25%) Nausea (23%)

AST, aspartate aminotransferase.

\*Range provided for different treatment arms and dose levels.


found to significantly reduce CMV reactivation, use of preemptive anti-CMV therapy, and all-cause mortality by week 24 posttransplantation (Figure 3). Letermovir had a favorable adverse event profile and high treatment completion rate (71%) despite being started preengraftment in a majority of patients (Table 2). Reduction in CMV reactivation and mortality was prominent in patients at higher risk of CMV reactivation and CMV disease, including those undergoing haploidentical HCT or mismatched-donor HCT and those receiving antithymocyte globulin. All-cause mortality was nonsignificantly lower in patients who received letermovir compared with placebo by week 48. The results of this trial led to regulatory approvals by the US Food and Drug Administration, European Medicines Agency, and Health Canada in late 2017.<sup>44-46</sup>

Letermovir is not myelosuppressive and is available in oral and IV formulations, allowing treatment to start a median of 9 days after HCT in the phase 3 trial. Letermovir is excreted by the liver and does not require dose adjustments based on renal or hepatic function except in patients with advanced cirrhosis (Child-Pugh class C).<sup>44,47</sup> Although pharmacokinetic studies have found that letermovir increased exposure to certain drugs,<sup>44</sup> including atorvastatin, tacrolimus, sirolimus, midazolam, and other medications that may require dosing adjustments, letermovir itself only required dose adjustment (50% reduction) when administered with cyclosporine.<sup>48</sup> Detailed letermovir characteristics are presented in Table 3.

It is important to note that the last 2 phase 3 trials of CMV prophylaxis conducted in patients undergoing HCT<sup>31,32</sup> imputed premature trial discontinuations for any reason (eg, withdrawal of consent, death, or loss to follow-up) as primary end point events, a conservative approach requested by regulatory agencies, which helps inform the clinical benefit and drug tolerability of the overall strategy. However, for the letermovir phase 3 trial, the proportion of patients with CMV-specific end points was 25 (7.7%) of 325 at the end of the treatment period (week 14, day + 100). Of these events, 12 (3.7%) occurred after patients had ended letermovir treatment for a median of 43 days (range, 14-75 days), and 1 patient began preemptive therapy for CMV within the week-14 study window after stopping letermovir. Another 12 events (3.7%) of preemptive therapy occurred while patients were receiving letermovir, but 10 of these events had nonquantifiable (<137 IU/mL) CMV DNA in the central laboratory; only 2 patients (0.6%) had quantifiable CMV viral loads at the time of preemptive therapy, and in 1 (0.3%) of these 2 patients, a mutation (*UL56* V236M) that confers letermovir resistance was documented.<sup>31</sup> Furthermore, no mutations associated resistance were found in patients who experienced CMV reactivation after discontinuation of letermovir.<sup>49</sup> An additional mutation (*UL56* C325W) was identified in 1 of 48 patients who began letermovir treatment with detectable CMV DNA (not part of the primary efficacy population); the patient developed breakthrough CMV viremia a few weeks into treatment.<sup>43,44</sup> Therefore, the on-treatment efficacy of letermovir when used in patients without CMV viremia at the start of prophylaxis was high.

## Discussion

CMV infection has been an obstacle to improved outcomes for patients who undergo allogeneic HCT and are CMV seropositive. Several studies in the past 3 decades have evaluated different antiviral agents in an attempt to find a safe and effective agent



**Figure 3. Forest plots summarizing outcomes of trials of antiviral prophylaxis vs placebo in HCT patients. (A) All-cause mortality. (B) CMV disease. (C) CMV infection (reactivation). (D) Preemptive therapy. BID, twice per day; df, degree of freedom.**

to be used as universal prophylaxis. The scope of the treatments covered in this review highlights the longstanding search for suitable CMV prophylaxis stretching from 1981 to present day.

The randomized trials reviewed demonstrate that among the 6 antiviral therapies studied, ganciclovir and letermovir were the most effective in reducing incidence of CMV reactivation when used as universal prophylaxis agents. Furthermore, CMV disease rates have decreased over the study period (Figure 3), in part because of

the introduction of more sensitive molecular methods for CMV surveillance and use of preemptive therapy during this time.<sup>50,51</sup>

Given the known disadvantages of preemptive therapy, such as treatment with drugs that have frequent toxic effects and an increased overall risk of mortality associated with CMV reactivation, the results presented suggest that patients undergoing allogeneic HCT would significantly benefit from universal prophylaxis with an agent that is tolerable after HCT. The data suggest that although




Figure 3. (Continued).


effective at reducing CMV reactivation and disease, ganciclovir use cannot be recommended as a universal prophylaxis agent because of an increased risk of myelosuppression and subsequent drug discontinuation.

In contrast, the data suggest that letermovir has an excellent safety profile, and its use should be considered for this indication in patients at risk. Letermovir was associated with a decrease in CMV-related outcomes and all-cause mortality through 24 weeks after HCT. These benefits are likely due in part to its tolerability, which allowed patients to continue treatment through week 14 post-transplantation, and the possibility of administering IV treatment in patients who were acutely ill or could not take oral medications. Although there were several cases of CMV reactivation in the letermovir arm in the phase 3 trial, a majority of these occurred after

the period of drug administration or in patients who discontinued letermovir therapy prematurely.<sup>31</sup> Given these data, weekly surveillance for CMV reactivation during administration of letermovir may not be necessary for a majority of patients; targeted testing when CMV reactivation is clinically suspected may be a reasonable approach, including the evaluation of fever, cytopenias, or clinical syndromes that could be due to CMV disease. CMV monitoring after discontinuation of letermovir prophylaxis is advisable in patients who remain at higher risk of CMV infection, especially those with GVHD.

Risk of CMV reactivation remains a concern among high-risk patients undergoing HCT, including those undergoing haploidentical HCT, cord-blood recipients, ex vivo T cell-depleted graft recipients, antithymocyte globulin recipients, and patients with grade

**Table 3. Letermovir characteristics and clinical guide**

Characteristic	Key information	Practical recommendations by authors
Chemical name	(4S)-2-[8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid	—
Chemical structure		—
Other names	BAY-73-6327, AIC-090027, AIC-246, MK-8228, Prevymis	—
Mechanism of action	Inhibition of human CMV terminase complex (UL51, UL56, UL89) by binding to UL56, UL51, or both <sup>39-41,67</sup>	—
Antiviral activity	Active against human CMV; median EC <sub>50</sub> 2.1 nM (range, 0.7-6.1 nM) against all CMV gB genotypes <sup>44,68</sup> No activity against other herpesviruses No antagonism when combined with CMV DNA polymerase inhibitor ganciclovir, foscarnet, or cidofovir <sup>69</sup>	Patients should receive antiviral prophylaxis against HSV and VZV with acyclovir, valacyclovir, or famciclovir as clinically indicated <sup>31</sup>
Letermovir resistance	UL56 V236M clinically resistant mutant has been identified in patients in phase 2 <sup>35,70</sup> and phase 3 trials <sup>31,49</sup> ; UL56 C325W breakthrough mutant was also identified in phase 3 trial in patient who began treatment with letermovir with detectable plasma CMV DNA (not part of primary efficacy population) <sup>43,44</sup> UL56 V236M and other letermovir-associated UL56 <sup>71,72,74,75</sup> and UL51 <sup>67</sup> mutations have been identified in vitro	Letermovir resistance testing is available in research <sup>71,72</sup> and reference <sup>73</sup> laboratories.
Approved indication	Prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic HCT <sup>44-46</sup>	Phase 3 trial comparing valganciclovir vs letermovir for CMV prophylaxis in CMV donor-seropositive, CMV-seronegative kidney transplant recipients is ongoing <sup>76</sup> Letermovir has been used for secondary CMV prophylaxis in solid organ transplant recipients with ganciclovir-resistant infections <sup>77</sup>
Formulations	Tablets: 240 and 480 mg  IV: 240 mg per 12 mL and 480 mg per 24 mL in single-dose vials (20 mg/mL) dissolved in hydroxypropyl-β-cyclodextrin, at ratio of 1800 mg per 240 mg of letermovir <sup>31,78</sup>	In HCT clinical trial, 26% of patients received IV letermovir for median of 12 d, <sup>31</sup> usually in setting of mucositis or other gastrointestinal issues that precluded oral administration; given higher bioavailability of IV letermovir, consider starting treatment with IV formulation in similar situations  Although IV administration of letermovir is advisable for patients who cannot take oral tablets, and letermovir package insert does not recommend it because of lack of data, <sup>44</sup> we have been successful in administering crushed letermovir tablets via gastrostomy tube in the outpatient setting
Dosage	480 mg per d 240 mg per d when coadministered with cyclosporine <sup>31,48</sup>	Letermovir exposure in patients receiving 240 mg per d of letermovir and concomitant cyclosporine was ~50% higher than in patients who received 480 mg per d of letermovir without concomitant cyclosporine use <sup>31</sup>
Bioavailability	35% of 480 mg per d dose without cyclosporine use <sup>31</sup> 85% of 240 mg per d dose with cyclosporine use <sup>31</sup> No appreciable food effect; t <sub>1/2</sub> 11 to 18 h <sup>79</sup>	Letermovir can be taken with or without food  No plasma letermovir concentration measurements available in reference laboratories to date
Metabolism	Hepatic uptake via OATP1B1/3, 93% excreted in feces, 70% unchanged; highly protein bound in plasma (99%) <sup>44</sup> Substrate of metabolizing enzymes CYP3A, CYP2D6, UGT1A1, UGT1A3; transporters OATP1B1/3 and P-gp. <sup>44</sup>	These metabolism pathways should be taken into consideration when administering concomitant medications not mentioned below
Drug interactions	Drug-drug interactions are likely more intense if using concomitant cyclosporine  Via CYP3A inhibition (weak to moderate)  Increased levels of amiodarone, antidiabetic agents (glyburide, repaglinide, rosiglitazone), fentanyl, midazolam (2.0× AUC), quinidine, sirolimus (3.0× AUC), tacrolimus (1.8× AUC) <sup>48,80</sup>  Via induction of CYP2C9/19 (weak to moderate)	Empirical dose adjustment of tacrolimus or sirolimus used for GVHD prophylaxis usually depends on drug levels when letermovir is started, as well as desired target trough levels; in our experience, in patients with low levels at beginning of coadministration (≤4 ng/mL), tacrolimus and sirolimus levels can be monitored without empirical adjustments; for patients with levels >8 ng/mL, empirical reductions of 50% and monitoring of drug levels are advisable  Consider reducing dose of statins if coadministered; we favor use of pravastatin or rosuvastatin given their lack of significant CYP metabolism <sup>81</sup>

AUC, area under the curve; GFR, glomerular filtration rate.

Table 3. (continued)

Characteristic	Key information	Practical recommendations by authors
	Decreased levels of voriconazole ( $0.56 \times$ AUC), <sup>79</sup> warfarin, phenytoin, proton pump inhibitors (omeprazole, pantoprazole)  Via OATP1B1/3  Increased levels of statins: atorvastatin ( $3.0 \times$ AUC), fluvastatin, lovastatin, pravastatin, rosuvastatin <sup>82,83</sup>  Increased levels of cyclosporine ( $1.7 \times$ AUC) <sup>48,80</sup>  No significant interactions in studies with acyclovir, digoxin, mycophenolate, posaconazole, <sup>79</sup> ethinyl estradiol, levonorgestrel <sup>44</sup>	
Contraindications	Pimozide and ergotamine, because of letermovir inhibition of CYP3A and increased levels of pimozide (increased QTc) and ergot alkaloids (ergotism) <sup>44</sup>  Pitavastatin and simvastatin if given concurrently with cyclosporine, because of increased statin levels via OATP1B1/3 <sup>44</sup>	These are uncommonly used drugs in HCT patients
Common adverse events	Nausea, vomiting, diarrhea, peripheral edema, cough, headache, fatigue, and abdominal pain ( $>10\%$ and $>2\%$ over placebo events) <sup>31,36,44</sup>	Consider letermovir as potential cause of persistent nausea or vomiting
Adverse events of note	Atrial fibrillation or flutter occurred in 4.6% of letermovir-treated patients vs 1% in those who received placebo <sup>31</sup> ; letermovir does not prolong QTc interval <sup>31,44</sup>  Alanine aminotransferase levels $>5 \times$ ULN were 3.5% in letermovir-treated patients vs 1.6% in those receiving placebo <sup>31</sup>	We would not start letermovir soon after conditioning regimens that involve use of CYP-metabolized drugs (eg, busulfan, cyclophosphamide); we would also withhold it during or right after posttransplantation cyclophosphamide administration to minimize risk of hepatotoxicity resulting from drug-drug and drug-metabolite interactions
Renal dysfunction	Increased letermovir exposure in patients with GFR $<60$ mL/min ( $<2$ -fold) <sup>84</sup> ; increased exposure does not require dose adjustments <sup>44</sup>  No dosing recommendations for GFR $<10$ mL/min <sup>31,44</sup>	Some caution is advised if GFR $<50$ mL/min and using IV formulation because of potential hydroxypropyl- $\beta$ -cyclodextrin accumulation and consequent osmotic toxicity <sup>44,78</sup>  The phase 3 trial enrolled patients with GFR $>10$ mL/min, yet no increased nephrotoxicity was observed <sup>31</sup>  No recommendation for severe renal impairment based on lack of data in this subpopulation; consider risks and benefits of letermovir prophylaxis for patients in this situation
Liver dysfunction	Patients with cirrhosis and moderate liver dysfunction (Child-Pugh class B) have $<2$ -fold higher letermovir exposures; patients with severe liver dysfunction (Child-Pugh class C) have $\sim$ fourfold increased letermovir exposures <sup>47</sup>	No letermovir dose adjustments are necessary for patients with cirrhosis and mild to moderate liver dysfunction (Child-Pugh class A or B), but letermovir is not recommended for cirrhotic patients with severe impairment (Child-Pugh class C) <sup>44</sup>

AUC, area under the curve; GFR, glomerular filtration rate.

$\geq 2$  GVHD requiring systemic glucocorticoids for treatment. As such, letermovir use may be preferentially considered in this patient population to prevent CMV reactivation. However, because letermovir does not have any activity against other human herpesviruses, concomitant acyclovir, valacyclovir, or famciclovir should be prescribed to reduce the risk of herpes simplex and varicella zoster clinical events.

On the basis of the criteria for study inclusion at the onset of this review, the trials presented are compelling in their quality. This review prioritized the selection of prospective, randomized studies, most of them double blinded and placebo controlled, which allow more direct comparisons. Through randomization, these studies minimized selection bias and addressed the most important outcomes in thoroughly understanding the feasibility of an antiviral CMV prophylaxis: the impact of the intervention on CMV infection incidence and all-cause mortality. The large number of overall participants also strengthens the qualitative conclusions reached by this review.

A key limitation of the evidence is that many of the studies identified had a small sample size. Only 3 studies had established dosing regimens and large sample sizes ( $N > 300$  patients). Another 3 studies evaluated varying drug doses, affecting the confidence of the overall outcome. Most of the trials included in this review had

wide CIs, making it difficult to measure the true efficacy of these interventions. Heterogeneity among studies resulting from vastly differing interventional methods, outcome measures, and study designs over  $>30$  years further limited their comparability, so a formal metaanalysis was not pursued. Three earlier studies also lacked details about primary study end points and experimental design.<sup>17,18,20</sup> Changes in diagnostic sensitivity is another confounding factor when analyzing the results. Because culture-based methods are less sensitive than molecular methods for CMV detection,<sup>51</sup> antiviral interventions during the era of culture-based testing may have seemed more favorable than they were in actuality.

The results from this review reflect the current clinical consensus that most antiviral prophylaxis options to date have been inadequate in overall efficacy, and those that are efficacious against CMV reactivation introduce undesirable toxicities that limit their use. Although the decision to pursue CMV prophylaxis in post-HCT patients has historically been nuanced to balance drug-related toxicity with CMV-related outcomes, the results of recent studies have changed this landscape.

Patients at increased risk for primary CMV reactivation and CMV disease are most likely to benefit from anti-CMV prophylaxis. Additional research is warranted to further refine which particular HCT populations would benefit most from anti-CMV prophylaxis in a rapidly evolving landscape. Further research is also warranted to study the impact of



CMV surveillance after the prophylactic period, the optimal threshold at which to initiate preemptive therapy after prophylaxis, and the role of CMV-specific immune monitoring for guiding prophylactic and preemptive CMV strategies.<sup>49,52-55</sup> These parameters will remain fluid and are likely to change in the future with the incorporation of CMV immunotherapies<sup>56-61</sup> and CMV vaccines.<sup>62-66</sup>

## Acknowledgments

The authors thank professor Robert H. Rubin for his enduring mentorship in the study of CMV in transplantation and for his discussion of ideas presented here.

M.P.C. receives salary support from the Detweiler Travelling Fellowship, provided by the Royal College of Physicians and Surgeons of Canada.

## Authorship

Contribution: F.M.M. and K.C. conceptualized this systematic review; K.C., M.P.C., and F.M.M. performed data collection and analyses; K.C. wrote the first draft of the manuscript; M.P.C., S.P.H., H.E., and F.M.M.

revised the manuscript and provided intellectual content; and all authors reviewed the manuscript and agreed to its submission in its current form.

Conflict-of-interest disclosure: S.P.H. has received institutional research support from Merck. H.E. has participated in advisory boards for Chimerix, Clinigene, and Merck. F.M.M. has received institutional research support from Astellas, Chimerix, Merck, and Shire and consulting honoraria from Alexion, Chimerix, Fate Therapeutics, GlaxoSmithKline, LFB, Merck, Roche Molecular Diagnostics, and Shire. The remaining authors declare no competing financial interests.

ORCID profiles: K.C., 0000-0001-8815-0641; M.P.C., 0000-0002-4867-2063; S.P.H., 0000-0002-4271-7443; F.M.M., 0000-0002-3708-8734.

Correspondence: Francisco M. Marty, Division of Infectious Diseases, Dana-Farber Cancer Institute and Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115; e-mail: fmarty@bwh.harvard.edu.

## REFERENCES

- Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. *Clin Infect Dis*. 2010;50(11):1439-1447.
- Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. *J Gen Virol*. 2006;87(Pt 7):1763-1779.
- Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. *J Gen Virol*. 1996; 77(Pt 12):3099-3102.
- Buckner CD, Epstein RB, Rudolph RH, Clift RA, Storb R, Thomas ED. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. *Blood*. 1970;35(6):741-750.
- Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. *Biol Blood Marrow Transplant*. 2003;9(9):543-558.
- Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. *Blood Rev*. 2017;31(3):173-183.
- Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. *Hematol Oncol Stem Cell Ther*. 2017;10(4):233-238.
- Yong MK, Ananda-Rajah M, Cameron PU, et al. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. *Biol Blood Marrow Transplant*. 2017; 23(11):1961-1967.
- Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. *Blood*. 2016;127(20):2427-2438.
- Rubin RH. Preemptive therapy in immunocompromised hosts. *N Engl J Med*. 1991;324(15):1057-1059.
- Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. *Transpl Int*. 2006;19(1):2-11.
- Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. *Lancet Haematol*. 2016;3(3):e119-e127.
- George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. *Transpl Infect Dis*. 2010;12(4):322-329.
- Moher D, Shamseer L, Clarke M, et al; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev*. 2015;4:1.
- Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen, Denmark: Nordic Cochrane Centre, Cochrane Collaboration; 2014.
- Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. *Ann Intern Med*. 2015;162(1):1-10.
- Gluckman E, Lotsberg J, Devergie A, et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. *Lancet*. 1983;2(8352): 706-708.
- Hann IM, Prentice HG, Blacklock HA, et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. *Br Med J (Clin Res Ed)*. 1983;287(6389):384-388.
- Saral R, Burns WH, Laskin OL, Santos GWLP, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. *N Engl J Med*. 1981;305(2):63-67.

20. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. *Bone Marrow Transplant*. 1986;1(2):185-192.
21. Prentice HG, Gluckman E, Powles RL, et al; European Acyclovir for CMV Prophylaxis Study Group. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. *Lancet*. 1994;343(8900):749-753.
22. Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. *Blood*. 2006;107(5):1800-1805.
23. Ljungman P, de La Camara R, Milpied N, et al; Valacyclovir International Bone Marrow Transplant Study Group. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. *Blood*. 2002;99(8):3050-3056.
24. Burns LJ, Miller W, Kandaswamy C, et al. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. *Bone Marrow Transplant*. 2002;30(12):945-951.
25. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. *Ann Intern Med*. 1993;118(3):173-178.
26. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. *Ann Intern Med*. 1993;118(3):179-184.
27. Szer J, Durrant S, Schwarzer AP, et al. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. *Intern Med J*. 2004;34(3):98-101.
28. Winston DJ, Yeager AM, Chandrasekar PH, Snyderman DR, Petersen FB, Territo MC; Valacyclovir Cytomegalovirus Study Group. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. *Clin Infect Dis*. 2003;36(6):749-758.
29. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. *Blood*. 2008;111(11):5403-5410.
30. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. *Blood*. 1996;88(10):4063-4071.
31. Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. *N Engl J Med*. 2017;377(25):2433-2444.
32. Marty FM, Winston DJ, Chemaly RF, et al. Brincidofovir for prevention of cytomegalovirus (CMV) after allogeneic hematopoietic cell transplantation (HCT) in CMV-seropositive patients: a randomized, double-blind, placebo controlled, parallel-group phase 3 trial [abstract]. *Biol Blood Marrow Transplant*. 2016;22(3):S23. Abstract 5.
33. Marty FM, Winston DJ, Rowley SD, et al; CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. *N Engl J Med*. 2013;369(13):1227-1236.
34. Marty FM, Ljungman P, Papanicolaou GA, et al; Maribavir 1263-300 Clinical Study Group. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. *Lancet Infect Dis*. 2011;11(4):284-292.
35. Chemaly RF, Ullmann AJ, Stoelben S, et al; AIC246 Study Team. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. *N Engl J Med*. 2014;370(19):1781-1789.
36. Krosky PM, Baek M-C, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. *J Virol*. 2003;77(2):905-914.
37. Hamirally S, Kamil JP, Ndassa-Colday YM, et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. *PLoS Pathog*. 2009;5(1):e1000275.
38. Marty FM, Boeckh M. Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed? *Curr Opin Virol*. 2011;1(6):555-562.
39. Weber O, Bender W, Eckenberg P, et al. Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. *Antiviral Res*. 2001;49(3):179-189.
40. Reefschaeger J, Bender W, Hallenberger S, et al. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. *J Antimicrob Chemother*. 2001;48(6):757-767.
41. Lischka P, Hewlett G, Wunberg T, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. *Antimicrob Agents Chemother*. 2010;54(3):1290-1297.
42. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. *J Virol*. 2011;85(20):10884-10893.
43. Ligat G, Cazal R, Hantz S, Alain S. The human cytomegalovirus terminase complex as an antiviral target: a close-up view. *FEMS Microbiol Rev*. 2018;42(2):137-145.
44. US Food and Drug Administration. PREVYMIS (letermovir) tablets and PREVYMIS (letermovir) injection. [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm). Accessed 28 March 2018.
45. European Medicines Agency. Prevymis (letermovir). [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004536/human\\_med\\_002200.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004536/human_med_002200.jsp&mid=WC0b01ac058001d124). Accessed 29 March 2018.

46. Health Canada. Prevymis. <https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=95817>. Accessed 29 March 2018.
47. Kroppeit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. *Br J Clin Pharmacol*. 2017;83(12):2678-2686.
48. Kroppeit D, von Richter O, Stobernack HP, Rübsamen-Schaeff H, Zimmermann H. Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects. *Clin Pharmacol Drug Dev*. 2018;7(1):9-21.
49. Marty FM, Maertens J, Badshah C. Letermovir prophylaxis for cytomegalovirus. *N Engl J Med*. 2018;378(10):965.
50. Einsele H, Ehninger G, Steidle M, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. *Lancet*. 1991;338(8776):1170-1172.
51. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. *Blood*. 1995;86(7):2815-2820.
52. Tey S-K, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. *PLoS One*. 2013;8(10):e74744.
53. Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon- $\gamma$ -release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. *J Infect Dis*. 2016;213(11):1701-1707.
54. Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. *Curr Infect Dis Rep*. 2018;20(4):4.
55. Khanna R. Immune monitoring of infectious complications in transplant patients: an important step towards improved clinical management. *J Clin Microbiol*. 2018;56(4):1-6.
56. Trivedi D, Williams RY, O'Reilly RJ, Koehne G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. *Blood*. 2005;105(7):2793-2801.
57. Hanley PJ, Cruz CRY, Savoldo B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. *Blood*. 2009;114(9):1958-1967.
58. Micklethwaite KP, Clancy L, Sandher U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. *Blood*. 2008;112(10):3974-3981.
59. Koehne G, Hasan A, Dubrovina E, et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. *Biol Blood Marrow Transplant*. 2015;21(9):1663-1678.
60. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. *J Clin Oncol*. 2017;35(31):3547-3557.
61. Neuenhahn M, Albrecht J, Odendahl M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT. *Leukemia*. 2017;31(10):2161-2171.
62. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Infect Dis*. 2012;12(4):290-299.
63. La Rosa C, Longmate J, Lacey SF, et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant [published correction appears in *J Infect Dis*. 2013;208(6):1038]. *J Infect Dis*. 2012;205(8):1294-1304.
64. La Rosa C, Longmate J, Martinez J, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. *Blood*. 2017;129(1):114-125.
65. Schmitt M, Schmitt A, Wiesneth M, et al. Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses. *Theranostics*. 2017;7(6):1705-1718.
66. Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. *Lancet Haematol*. 2016;3(2):e87-e98.
67. Chou S. A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance. *Antiviral Res*. 2017;148:1-4.
68. Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. *Antimicrob Agents Chemother*. 2012;56(2):1135-1137.
69. Wildum S, Zimmermann H, Lischka P. In vitro drug combination studies of letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. *Antimicrob Agents Chemother*. 2015;59(6):3140-3148.
70. Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. *Antiviral Res*. 2015;116:48-50.
71. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. *Antimicrob Agents Chemother*. 2015;59(10):6588-6593.
72. Chou S. Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds. *Antimicrob Agents Chemother*. 2017;61(11):e01325-e17.
73. Viracor Eurofins Clinical Diagnostics. CMV resistance: letermovir. <https://www.viracor-eurofins.com/test-menu/30722-cmv-resistance-letermovir/>. Accessed 11 July 2018.
74. Chou S, Satterwhite LE, Ercolani RJ. A new locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir [published online ahead of print 18 June 2018]. *Antimicrob Agents Chemother*. doi:10.1128/AAC.00922-18.

75. Piret J, Goyette N, Boivin G. Drug susceptibility and replicative capacity of multidrug-resistant recombinant human cytomegalovirus harboring mutations in *UL56* and *UL54* genes. *Antimicrob Agents Chemother*. 2017;61(11):e01044-e17.
76. Letemovir versus valganciclovir to prevent human cytomegalovirus disease in kidney transplant recipients (MK-8228-002). <https://clinicaltrials.gov/ct2/show/NCT03443869>. Accessed 11 July 2018.
77. Chong PP, Teiber D, Prokesch BC, et al. Letemovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (*UL97* mutation). *Transpl Infect Dis*. 2018;10:e12965.
78. Erb-Zohar K, Kropf D, Scheuenpflug J, et al. Intravenous hydroxypropyl  $\beta$ -cyclodextrin formulation of letemovir: a phase I, randomized, single-ascending, and multiple-dose trial. *Clin Transl Sci*. 2017;10(6):487-495.
79. Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and tolerability of letemovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. *J Clin Pharmacol*. 2018;58(7):897-904.
80. Amundsen R, Christensen H, Zabihiyan B, Åsberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. *Drug Metab Dispos*. 2010;38(9):1499-1504.
81. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol*. 2005;19(1):117-125.
82. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. *Drug Metab Pharmacokinet*. 2011;26(3):220-227.
83. Karlgren M, Vildhede A, Norinder U, et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. *J Med Chem*. 2012;55(10):4740-4763.
84. Kropf D, Scheuenpflug J, Erb-Zohar K, et al. Pharmacokinetics and safety of letemovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment. *Br J Clin Pharmacol*. 2017;83(9):1944-1953.